Syner-med (pharmaceutical Products) Limited

Syner-Med Pharmaceutical Products Ltd, based in London, UK, is a small, active company established 30 years ago. With 13 employees and £7,920,444 in assets, it operates from a virtual address – a detail worth noting as 175 companies share the same location. The company is led by seven directors and owned by a solo founder, Bhatti Dipak Devji. It regularly imports optical and medical tools and devices (11 months) and exports miscellaneous chemical products (17 months).

The company’s website paints a picture of a biopharmaceutical firm dedicated to innovation in healthcare, focusing on licensing, clinical development, and commercialization to address unmet clinical needs. It partners with healthcare professionals and operates across Vascular Access, Urology, and Urogynaecology fields, boasting a global reach through qualified partners. The website highlights a showroom in Harrods, London, for its piano restoration division.

Financially, Syner-Med shows some concerning trends. Net losses increased significantly, from £1.4 million to £4.4 million, while cash reserves dropped by 65% to just £480,000. Trade debtors rose by 60%, suggesting potential issues with customer payments, and bank borrowings increased by 100% to £29,000. Creditors also increased by 30% to £1.2 million. Despite these pressures, the company’s small size (meeting two of three criteria for turnover under £10.2m, assets under £5.1m, and fewer than 50 employees) allows for agility. The lack of an auditor mentioned likely reflects its exemption as a small company, meaning the figures are unaudited.

While the company’s website showcases a global reach and high-end services, the financial data reveals a period of strain. Whether Syner-Med can navigate these challenges and sustain its operations remains to be seen.

Registered in England/Wales under the registration number 02950518, with a registered address at EC1M 4JN, United Kingdom, London, 82 St John Street.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.